Who published this market news?

TradingView published this market news item.

bioAffinity Technologies Q2 CyPath® Lung Sales More Than Double Year‑Over‑Year

bioAffinity Technologies reported CyPath® Lung commercial sales grew more than 200% year‑over‑year in Q2 2026.Key Highlights:Original SEC Filing: bioAffinity Technologies, Inc. [ BIAF ] - 8-K - Jul. 07, 2026This is an AI-powered summary. It may contain inaccuracies. Consider verifying important inf…

bioAffinity Technologies reported CyPath® Lung commercial sales grew more than 200% year‑over‑year in Q2 2026.

Key Highlights:

Q2 2026 CyPath® Lung test volume rose >200% vs Q2 2025, signaling accelerating commercial adoption.
Quarterly tests increased >30% vs Q1 2026, driven by higher utilization among existing clients.
Physician offices ordering CyPath® Lung grew 155% vs Q2 2025, indicating expanding clinical uptake.
Nearly 3,000 CyPath® Lung tests performed since launch; company pursuing larger clinical study and oncology uses.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.